Journal article

Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: A pilot study

Ringe J, Dorst A, Faber H, Kipshoven C, Rovati L, Setnikar I ...see all

Rheumatology International, vol. 25, issue 4 (2005) pp. 296-300

  • 14

    Readers

    Mendeley users who have this article in their library.
  • 7

    Citations

    Citations of this article.
Sign in to save reference

Abstract

In a three-year pilot study on 52 women with severe postmenopausal osteoporosis, treatment with etidronate followed by calcium and vitamin D (ECaD) was compared to etidronate followed by monofluorophosphate, calcium and vitamin D (EFCaD). BMD in lumbar spine, total hip and femoral neck increased significantly more with EFCaD than with ECaD. Pain-mobility score decreased significantly more with EFCaD than with ECaD (p=0.006). New vertebral fractures occurred in three patients under EFCaD (12%) and in nine under ECaD (35%), (p=0.048). Three patients under EFCaD (12%) and 15 under ECaD (58%) did not respond to therapy (p of difference=0.001). Mild or moderate adverse reactions were reported by 25 patients, with no significant difference between the two groups. The pilot study suggests that etidronate, sequentially followed by monofluorophosphate, could be a safe, effective and relatively inexpensive therapy in severe postmenopausal osteoporosis. © Springer-Verlag 2005.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • J. D. Ringe

  • A. Dorst

  • H. Faber

  • C. Kipshoven

  • L. C. Rovati

  • I. Setnikar

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free